Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compugen ( (CGEN) ) just unveiled an announcement.
On September 16, 2025, Compugen Ltd. conducted its 2025 Annual General Meeting of Shareholders, where all proposals were approved by the necessary majority vote. This approval signifies continued shareholder support and could potentially strengthen Compugen’s strategic initiatives and market position in the biotechnology sector.
The most recent analyst rating on (CGEN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
Compugen’s overall stock score is primarily influenced by its financial performance and technical analysis. While there are signs of operational improvement and strategic advancements, the company faces significant challenges in profitability and market competition. The technical indicators suggest a bearish trend, and the valuation is weak due to negative earnings. The earnings call provided some positive insights, but these are not enough to offset the overall risks.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. operates within the biotechnology industry, focusing on the development of therapeutic and diagnostic products. The company is known for its computational predictive discovery capabilities, which it leverages to identify novel drug targets and biomarkers, primarily in the field of immuno-oncology.
Average Trading Volume: 224,337
Technical Sentiment Signal: Sell
Current Market Cap: $129.1M
For a thorough assessment of CGEN stock, go to TipRanks’ Stock Analysis page.